Laidlaw acts as Exclusive Placement Agent on the $9,200,000 Private Placement for Guerrilla RF
Laidlaw is pleased to have acted as Exclusive Placement Agent ont the $9.2 Million Private Placement for Guerrilla RF. Please follow the article below for additional information.
Laidlaw acts as Joint Book Runner on the $7,000,000 Initial Public Offering for NFT Gaming Company
Laidlaw is pleased to have acted as Joint Book Runner for the offering. Please read the article below for additional info.
Laidlaw acts as Exclusive Introducing Broker on NLS Pharmaceutics’ Closing of Initial Tranche of US$10.0 Million Purchase Agreement with BVF Partners L.P.
On December 14, 2022, NLS Pharmaceutics (NASDAQ:NLSP,)(NASDAQ:NLSPW) announced the closing of its previously publicized purchase agreement with BVF Partners L.P. (“BVF”) comprised of an initial closing of $10 million in exchange for 11,494,253 common shares (or equivalents), representing a purchase price per share of $0.87.
As part of the financing, in a second potential closing, BVF will have the right, following a successful end of phase 2 meeting with the U.S. Food and Drug Administration (“FDA”), among other closing conditions, to purchase units at a per unit purchase price of $1.50, which units will consist of common shares (or equivalents), as well as a common share warrant to purchase up to one and a half common shares at an exercise price of $2.03 per share. If this option is exercised in full, BVF will receive 20 million common shares plus common share warrants to purchase 20 million NLS common shares at $2.03 per share.
Laidlaw & Company (UK) Ltd. acted as exclusive introducing broker for the offering.
Laidlaw acts as Sole Placement Agent on the $4,000,000 NLS Pharmaceutics Ltd. Private Placement
Laidlaw is pleased to have acted as the Sole Placement Agent on the $4,000,000 Private Placement for NLS Pharmaceutics.
Laidlaw acts as Sole Book-Runner on the $5,750,000 Silo Pharma, Inc. Follow-On Offering
Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter’s Over-Allotment Option:
Laidlaw Capital Markets is pleased to announce the closing of its expanded and oversubscribed $10,000,000 financing for Perfect Moment.
Perfect Moment is a luxury sportswear brand that has become known as an iconic staple in winter wear. The Perfect Moment collections marry the extreme demands of nature with the world of fashion and can be found at Selfridges, Net-A-Porter, Matches, Saks Fifth Avenue, Neiman Marcus, Bloomingdales and FWRD.
Laidlaw acts as Sole-Book Runner on the $3,500,000 BioSig Technologies’ Follow-On Transaction.
Laidlaw Capital Markets is pleased to have acted as Sole-Book Runner on the $3,500,000 Common Stock transaction for BioSig Technologies (BSGM).
Laidlaw acts as Underwriter on the $367,886,900 Cohen & Steers Real Estate Opportunities and Income Fund Offering
Laidlaw Capital Markets is pleased to have acted as Underwriter on the $367,886,900 Cohen & Steers Real Estate Opportunities and Income Fund Offering alongside Bank of America, Morgan Stanley, Raymond James, UBS, & Wells Fargo.
Laidlaw Capital Markets acts as Co-Lead Bookrunner on Cingulate Inc’s (CING) $25,000,000 Offering.
Laidlaw Capital Markets is pleased to have been Co-Lead Bookrunner on Cingulate Inc’s (CING) $25,000,000 Offering. Cingulate utilizes its proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation products.